GAMMA Investing LLC Boosts Stake in Bruker Corporation $BRKR

GAMMA Investing LLC lifted its holdings in Bruker Corporation (NASDAQ:BRKR) by 139.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,225 shares of the medical research company’s stock after purchasing an additional 1,877 shares during the quarter. GAMMA Investing LLC’s holdings in Bruker were worth $133,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of BRKR. Sculptor Capital LP increased its position in Bruker by 51.6% during the first quarter. Sculptor Capital LP now owns 2,598,438 shares of the medical research company’s stock valued at $108,459,000 after acquiring an additional 884,423 shares during the last quarter. Brown Advisory Inc. increased its position in Bruker by 18.9% during the first quarter. Brown Advisory Inc. now owns 2,410,137 shares of the medical research company’s stock valued at $100,599,000 after acquiring an additional 383,425 shares during the last quarter. AQR Capital Management LLC increased its position in Bruker by 65.9% during the first quarter. AQR Capital Management LLC now owns 1,476,605 shares of the medical research company’s stock valued at $60,688,000 after acquiring an additional 586,516 shares during the last quarter. Goldman Sachs Group Inc. increased its position in Bruker by 107.3% during the first quarter. Goldman Sachs Group Inc. now owns 1,465,319 shares of the medical research company’s stock valued at $61,162,000 after acquiring an additional 758,301 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in Bruker by 5.8% during the first quarter. Charles Schwab Investment Management Inc. now owns 926,790 shares of the medical research company’s stock valued at $38,684,000 after acquiring an additional 50,537 shares during the last quarter. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Stifel Nicolaus set a $40.00 price objective on Bruker and gave the company a “hold” rating in a research report on Tuesday, August 5th. Barclays cut their price target on Bruker from $46.00 to $43.00 and set an “overweight” rating for the company in a report on Monday, August 4th. Bank of America cut their price target on Bruker from $61.00 to $50.00 and set a “buy” rating for the company in a report on Thursday, June 26th. Citigroup cut their price target on Bruker from $40.00 to $38.00 and set a “neutral” rating for the company in a report on Monday, August 4th. Finally, Jefferies Financial Group set a $60.00 price target on Bruker and gave the company a “buy” rating in a report on Monday, August 4th. Five research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $51.30.

Insider Activity

In other news, Director Cynthia M. Friend sold 3,535 shares of the firm’s stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $32.25, for a total value of $114,003.75. Following the completion of the sale, the director directly owned 18,016 shares of the company’s stock, valued at $581,016. This trade represents a 16.40% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 27.30% of the stock is owned by insiders.

Bruker Stock Performance

NASDAQ BRKR opened at $32.49 on Wednesday. The stock has a market capitalization of $4.93 billion, a PE ratio of 62.48, a P/E/G ratio of 4.29 and a beta of 1.22. The business has a 50 day simple moving average of $33.82 and a two-hundred day simple moving average of $37.69. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.61 and a quick ratio of 0.70. Bruker Corporation has a 1-year low of $28.53 and a 1-year high of $69.61.

Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Monday, August 4th. The medical research company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.01). The firm had revenue of $797.40 million for the quarter, compared to analysts’ expectations of $811.17 million. Bruker had a net margin of 2.31% and a return on equity of 17.89%. The business’s quarterly revenue was down .4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.52 EPS. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. On average, research analysts predict that Bruker Corporation will post 2.69 EPS for the current fiscal year.

Bruker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 3rd. Stockholders of record on Tuesday, September 23rd will be paid a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Tuesday, September 23rd. Bruker’s dividend payout ratio (DPR) is presently 38.46%.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.